QBIC and NOSHAQ seed finance new vub spin-off ABSCINT
Summary
Experienced management team ABSCINT has set up its operations in Liège, Belgium and appointed Karine Clauwaert as CEO together with Tony Lahoutte as Medical Director. The management team holds strong industry experience and expertise in the production of single domain antibodies, radiopharmaceuticals, and clinical translation of radiolabelled molecules. This is why UZ Brussel endorses, and invests in, this endeavor.” • Jean Van Nuwenborg (Qbic): "Combining single domain antibodies with radioactivity could significantly advance diagnosis of a vast array of diseases and improve outcomes for these patients. VIB has an excellent track record on translating basic scientific results into pharmaceutical, agricultural and industrial applications. We are the regional reference holder for all stakeholders in innovative R&I projects in health biotechnology and medical technologies, whether they are companies, research centers or universities.